人表皮生长因子受体2阳性非小细胞肺癌靶向治疗药物临床研究进展

Progress in clinical research of targeted drugs for HER2 positive non-small cell lung cancer

肺癌已成为全球癌症患者死亡的主要原因,非小细胞肺癌占肺癌的85%,人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性非小细胞肺癌恶性程度较高,具有较高的复发和死亡风险。针对HER2阳性非小细胞肺癌的靶向治疗已成为研究热点,现有的靶向药物主要包括酪氨酸激酶抑制剂、单克隆抗体、抗体-药物偶联物、双特异性抗体和抗体-放射性核素偶联物。然而,目前尚无临床指南建议的标准治疗方案。本文就HER2阳性非小细胞肺癌靶向治疗药物的最新临床研究结果进行综述。

Lung cancer has become the leading cause of cancer death worldwide.Non-small cell lung cancer(NSCLC)accounts for 85%of lung cancers.Human epidermal growth factor receptor 2(HER2)-positive NSCLC is highly aggressive and has a high risk of recurrence and death.Targeted therapy for HER2-positive NSCLC has become a research hotspot.The existing targeted drugs mainly include tyrosine kinase inhibitors,monoclonal antibodies,antibody-drug conjugates,bispecific antibodies,and antibody-radionuclide conjugates.However,there is still no standard treatment recommended by clinical guidelines for HER2-positive NSCLC.This article reviews the latest clinical research results of targeted therapy for HER2-positive NSCLC.